Dr. Joseph Mercola - Take Control of Your Health FDA Approves RSV Shot Despite High Infant Risk - AI Podcast
Jul 17, 2025
The recent approval of a new RSV shot for infants raises serious concerns as clinical trials show alarming side effects, including seizures and neurological reactions. Infants receiving the shot face a disproportionately high risk compared to their weight. Surprisingly, the injection doesn't effectively prevent the very infections it claims to target. The discussion also highlights the importance of breastfeeding and maternal health in protecting against RSV, alongside calls for transparency in monitoring post-approval outcomes.
AI Snips
Chapters
Transcript
Episode notes
High Risks in RSV Shot Trial
- Nearly 12% of infants receiving Merck's RSV shot experienced serious adverse events, including brain injuries and death.
- This high risk questions the safety of the shot despite its protective claims.
Uniform Dosing Poses Risk to Smaller Infants
- Only about 25 infants die yearly from RSV in the U.S., yet a fixed high dose is given to all babies regardless of weight.
- Small, preterm infants get a higher drug concentration, increasing their risk of adverse effects.
Neurological and Respiratory Risks Spike
- Neurologic events like seizures and brain injury were triple in the vaccinated group compared to placebo.
- Infants receiving the shot showed 3x higher upper respiratory infections, undermining its protective claims.